Skip to content

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Novo Nordisk shares jump on Wegovy heart benefit alongside weight loss

Novo Nordisk shares rose after data showed its weight loss drug led to protective cardiac benefits. IGTV financial analyst @AngelineOng hones in on the global obesity drug race.

Video poster image

(Video Transcript)

Contenders battle it out in obesity drug race

It’s all about obesity drugs, especially in the last few weeks, Novo Nordisk is rising and lifting the overall drug market here in Europe. This is after news at the weekend that Novo Nordisk released saying that its drug Wegovy, which is used for weight loss, has heart protective benefits.

Now, all this comes at a time when many contenders are trying to release their drugs and gain approval in this space. Eli Lilly, of course, one of them in the last week, has got the green light for its peer drug from the US and the UK.

But also wanting to show you AstraZeneca, because AstraZeneca earlier today announced that it had entered the race as well. It added an obesity drug via an acquisition of a drug from the biotech company, Ecogene. This is to develop and commercialise ECC5004.

AstraZeneca, Pfizer and Amgen jump in

Now, all this comes at a time when there's a space race in these obesity drugs. Pfizer, Amgen, some of the other drug makers that also have drugs in this space, showing you Amgen as well. However, it has to be said that Eli Lilly and Novo Nordisk currently are in the lead.

So where is the sala dressing? If you think the risks for these drugs that are still relatively untested are low, then perhaps you want to increase your exposure to these stocks because there is a huge amount of diabetes and obesity in first-world countries.

Obesity drug to hit market after Thanksgiving

And what's also key is that if you think that this is a very interesting space and could have potential upside, you want to pay more attention to the data about the cardiac benefits and also the potential impact if this drug is then rolled out to national health systems like the National Health Service in the UK.

Bear in mind, some of these drugs are expected to go on sale as soon as Thanksgiving is over.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Equities
  • Indices
  • Forex
  • Commodities
website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

" >


Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.